GLP-1 receptor agonists are among the most intensively studied peptides in metabolic research. This guide explains what GLP-1 is, how these peptides interact with the body's incretin system, and how the major research compounds, semaglutide, tirzepatide, and retatrutide, differ in the receptors they target.
GLP-1 (glucagon-like peptide-1) is a hormone released by cells in the intestine after eating. It belongs to a family of hormones called incretins, which help the body manage blood sugar. Natural GLP-1 stimulates insulin release when glucose is elevated, slows gastric emptying, and signals to the brain in ways associated with reduced appetite. One limitation is that it is broken down within minutes by an enzyme called DPP-4, the short half-life that GLP-1 receptor agonists were designed to solve.
A GLP-1 receptor agonist is a peptide engineered to activate the same receptor as natural GLP-1 while resisting enzymatic breakdown. Structural modifications, amino acid substitutions and a fatty acid chain that binds albumin in the blood, extend the half-life from minutes to days, allowing sustained receptor activation.
• Glucose-dependent insulin secretion: insulin release is enhanced mainly when blood glucose is elevated.
• Gastric emptying: the passage of food from the stomach is slowed.
• Central appetite signaling: brain receptors are engaged in pathways associated with satiety.
GLP-1 agonists are engineered to activate the incretin system and resist rapid enzymatic breakdown, extending their action from minutes to days.
Semaglutide targets the GLP-1 receptor alone. It is one of the most extensively characterized peptides in metabolic research and serves as a common reference point against which newer multi-receptor compounds are compared.
Tirzepatide is a dual agonist: in addition to the GLP-1 receptor, it activates the receptor for GIP (glucose-dependent insulinotropic polypeptide), a second incretin hormone. Researchers study whether engaging both incretin pathways produces effects on glucose handling and body weight that differ from single-receptor agonism.
Retatrutide adds a third target, the glucagon receptor, to GLP-1 and GIP activity. The glucagon receptor is of interest because of its role in energy expenditure and hepatic metabolism. Retatrutide is a newer investigational compound and a very active area of research.
Targets: GLP-1. Class: single agonist.
Targets: GLP-1 + GIP. Class: dual agonist.
Targets: GLP-1 + GIP + glucagon. Class: triple agonist.
The incretin system sits at the intersection of glucose regulation, appetite, gastric motility, and energy balance, processes central to metabolic science. Because peptides can be engineered to engage one, two, or three receptors with tunable selectivity and duration, they give researchers a precise toolkit for studying how each pathway contributes to metabolic outcomes.
Research use only. The information on this page is provided for educational purposes and refers to laboratory research material only. These peptides are not for human or veterinary use and are not intended to diagnose, treat, cure, or prevent any disease. Nothing here is medical advice.
